| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lilly Schwieler, Klas R Linderholm, Linda K Nilsson-Todd, Sophie Erhardt, Göran Engber. Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life sciences. vol 83. issue 5-6. 2008-09-16. PMID:18590745. |
clozapine has a remarkable efficacy in treatment-resistant schizophrenia and is one of the most effective antipsychotic drugs used today. |
2008-09-16 |
2023-08-12 |
rat |
| M-K Wu, C-Y Huang, Y J Liou, C-K Wang, S-D Le. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. International journal of obesity (2005). vol 32. issue 3. 2008-09-09. PMID:17955031. |
obese patients with schizophrenia being treated with clozapine and non-psychiatric obese are often assumed to share the same physiological changes in obesity. |
2008-09-09 |
2023-08-12 |
human |
| M-K Wu, C-Y Huang, Y J Liou, C-K Wang, S-D Le. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. International journal of obesity (2005). vol 32. issue 3. 2008-09-09. PMID:17955031. |
the aim of this study was to identify possible metabolic and hormonal differences between non-psychiatric obese subjects (ob) and obese patients with schizophrenia being treated with clozapine (osc). |
2008-09-09 |
2023-08-12 |
human |
| Jae Seung Chang, Yong Min Ahn, Hye Jean Park, Kyu Young Lee, Se Hyun Kim, Ung Gu Kang, Yong Sik Ki. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18370574. |
inadequate response to clozapine poses a substantial problem in the pharmaco-therapy of refractory schizophrenia. |
2008-09-03 |
2023-08-12 |
Not clear |
| D S Danilov, Iu G Tiul'pi. [Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 107. issue 2. 2008-08-26. PMID:18379518. |
a sample included 61 patients, 53 men and 8 women, with icd-10 episodic schizophrenia in the remission after treatment with atypical neuroleptics (risperidon, olanzapine, clozapine). |
2008-08-26 |
2023-08-12 |
Not clear |
| Zafiris J Daskalakis, Bruce K Christensen, Paul B Fitzgerald, Bertram Moller, Sarah I Fountain, Robert Che. Increased cortical inhibition in persons with schizophrenia treated with clozapine. Journal of psychopharmacology (Oxford, England). vol 22. issue 2. 2008-08-18. PMID:18308816. |
increased cortical inhibition in persons with schizophrenia treated with clozapine. |
2008-08-18 |
2023-08-12 |
human |
| Zafiris J Daskalakis, Bruce K Christensen, Paul B Fitzgerald, Bertram Moller, Sarah I Fountain, Robert Che. Increased cortical inhibition in persons with schizophrenia treated with clozapine. Journal of psychopharmacology (Oxford, England). vol 22. issue 2. 2008-08-18. PMID:18308816. |
the purpose of this study, therefore, was to examine the effects of clozapine on tms measures of ci and to compare these effects to unmedicated persons with schizophrenia and healthy subjects. |
2008-08-18 |
2023-08-12 |
human |
| Zafiris J Daskalakis, Bruce K Christensen, Paul B Fitzgerald, Bertram Moller, Sarah I Fountain, Robert Che. Increased cortical inhibition in persons with schizophrenia treated with clozapine. Journal of psychopharmacology (Oxford, England). vol 22. issue 2. 2008-08-18. PMID:18308816. |
our findings suggest that clozapine treatment is associated with greater ci in persons with schizophrenia and this increase may be related to potentiation of cortical gabaergic receptor mediated inhibitory neurotransmission. |
2008-08-18 |
2023-08-12 |
human |
| C E McOmish, E Burrows, M Howard, E Scarr, D Kim, H-S Shin, B Dean, M van den Buuse, A J Hanna. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Molecular psychiatry. vol 13. issue 7. 2008-08-13. PMID:17667964. |
phospholipase c-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. |
2008-08-13 |
2023-08-12 |
mouse |
| Carlo Rostagno, Gianni Di Norscia, Gian Framco Placidi, Gian Franco Gensin. Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. General hospital psychiatry. vol 30. issue 3. 2008-08-11. PMID:18433662. |
beta-blockers and ace inhibitors may allow resumption of clozapine in refractory schizophrenia in whom it was withdrawn for cardiotoxicity. |
2008-08-11 |
2023-08-12 |
Not clear |
| P Raju, G K Rao, G Davi. Pericardial effusion in patients with schizophrenia: are they on clozapine? Emergency medicine journal : EMJ. vol 25. issue 6. 2008-08-11. PMID:18499836. |
pericardial effusion in patients with schizophrenia: are they on clozapine? |
2008-08-11 |
2023-08-12 |
Not clear |
| P Raju, G K Rao, G Davi. Pericardial effusion in patients with schizophrenia: are they on clozapine? Emergency medicine journal : EMJ. vol 25. issue 6. 2008-08-11. PMID:18499836. |
clozapine is used in the treatment of resistant schizophrenia. |
2008-08-11 |
2023-08-12 |
Not clear |
| Daniel J Abrams, Lijun Zheng, Kevin S Choo, Jun J Yang, Wei Wei, Thomas J Anchordoquy, Nasser H Zawia, Karen E Steven. An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients. Schizophrenia research. vol 100. issue 1-3. 2008-08-01. PMID:18178385. |
an initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients. |
2008-08-01 |
2023-08-12 |
mouse |
| Daniel J Abrams, Lijun Zheng, Kevin S Choo, Jun J Yang, Wei Wei, Thomas J Anchordoquy, Nasser H Zawia, Karen E Steven. An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients. Schizophrenia research. vol 100. issue 1-3. 2008-08-01. PMID:18178385. |
while these data represent only an initial investigation, they none-the-less suggest that central administration of clozapine may be a viable alternate therapeutic approach for schizophrenia patients which may be effective in symptom reduction without causing behavioral or neurotoxic effects. |
2008-08-01 |
2023-08-12 |
mouse |
| Rajiv Tandon, R H Belmaker, Wagner F Gattaz, Juan J Lopez-Ibor, Ahmed Okasha, Bruce Singh, Dan J Stein, Jean-Pierre Olie, W Wolfang Fleischhacker, Hans-Juergen Moelle. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia research. vol 100. issue 1-3. 2008-08-01. PMID:18243663. |
clozapine was found to be more efficacious than other agents in treatment-refractory schizophrenia. |
2008-08-01 |
2023-08-12 |
Not clear |
| Sharmin Ghaznavi, Marina Nakic, Paul Rao, Jian Hu, Judson A Brewer, Jonas Hannestad, Zubin Bhagwaga. Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. The American journal of psychiatry. vol 165. issue 7. 2008-08-01. PMID:18593787. |
rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. |
2008-08-01 |
2023-08-12 |
Not clear |
| Janice Sepúlveda Reis, Tiago Alvarenga, Pedro Weslley S do Rosário, Patrícia A F C Menezes, Roberta Dos Santos Rocha, Saulo Purisc. [Diabetes mellitus associated with atypical antipsychotic medications: case report and review of the literature]. Arquivos brasileiros de endocrinologia e metabologia. vol 51. issue 3. 2008-07-31. PMID:17546250. |
we report the case of a 28-year-old patient with schizophrenia who was admitted with diabetic acidosis 1 month after the beginning of clozapine therapy. |
2008-07-31 |
2023-08-12 |
human |
| Jin Hun Kim, Daeho Kim, Stephen R Marde. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 4. 2008-07-22. PMID:18262321. |
time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. |
2008-07-22 |
2023-08-12 |
Not clear |
| Jin Hun Kim, Daeho Kim, Stephen R Marde. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 4. 2008-07-22. PMID:18262321. |
clozapine is known to be effective in treating schizophrenia patients with comorbid alcohol use disorders (aud). |
2008-07-22 |
2023-08-12 |
Not clear |
| Jin Hun Kim, Daeho Kim, Stephen R Marde. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 4. 2008-07-22. PMID:18262321. |
however, few prospective studies have examined the effect of clozapine on community survival of the patient, which is one of the most important indicators of success for patients with schizophrenia. |
2008-07-22 |
2023-08-12 |
Not clear |